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TEMPORAL EVOLUTION IN THE HISTOPATHOLOGIC DIAGNOSIS OF
BORDERLINE MELANOCYTIC LESIONS. Jason E. Frangos, Lyn Duncan and Alexa
B. Kimball. Departments of Dermatology and Dermatopathology, Massachusetts General
Hospital, Harvard Medical School, Boston MA. (Sponsored by Dr. Robert Tigelaar,
Department of Dermatology, Yale University School of Medicine).

While the incidence of cutaneous malignant melanoma has risen steeply over the past half
century, increases in the mortality rate have been relatively modest. In an effort to understand this
discrepancy, we sought to determine whether a shift toward more malignant diagnoses may have
been made by dermatopathologists (DPs) diagnosing severely dysplastic nevi over a time period
of 20 years. Forty biopsy slides of dysplastic nevi (28) and thin melanomas (12) from the period
1988-1990 were obtained from the pathology files of the Massachusetts General Hospital (MGH).
All DPs that had rendered an original diagnosis for any of the 40 slides as well as the current staff
in the MGH Dermatopathology department were invited to re-evaluate the slide-set. Three
original DPs and 3 current MGH staff DPs re-read the slide-set. The mean number of melanoma
diagnoses by the 6 study participants was 19.7 (median=19.5), an increase of 64% from the
original number of melanoma diagnoses in the slide set (12). For lesions originally diagnosed as
“Melanoma”, study participants had a high level of agreement between each other (kappa=0.74)
and between each rater and the original diagnosing DP (kappa=0.86). For lesions originally
diagnosed as “Not Melanoma” study participants had a low level of agreement between each
other (kappa=0.22) and a low level of agreement between each rater and the original diagnosing
DP (mean kappa=0.39). The results of this study indicate that a small set of DPs at a major
academic institution tended to read prior non-malignant diagnoses of borderline melanocytic
lesions as malignant but not to revise prior diagnoses of malignant melanoma as benign.
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INTRODUCTION
Cutaneous malignant melanoma (CMM) is a pigmented neoplasm of the skin that often
arises in pre-existing nevi, although half appear on previously normal appearing skin. The
cell of origin for malignant melanoma is the melanocyte, a pigmented cell derived from
the neural crest that is normally located in the basal layer of the epidermis. (1)

There is broad consensus that the worldwide incidence of CMM has been rising over the
last century. (2-7) It has been rising at different rates depending on the time epoch,
gender, age cohort or geographic location considered. The rate of rise has been
particularly steep during the most recent decades and has recently been characterized by
many in the medical community as an “epidemic”. (8-11) A number of researchers have
questioned whether the apparent rise in the incidence of CMM is real and have raised the
idea that it may be, at least in part, due to artifactual causes. (10, 12-18)

In the United States, the rise in incidence has been precipitous; in 2005, the age-adjusted
incidence rate of cutaneous melanoma in the U.S. among whites of both sexes was 26.4
per 100,000 per year. This represents an overall increase of approximately 200% since
1975 when the age adjusted incidence was 8.7 per 100,000 per year. (19) [Figure 1] In
contrast to the Caucasian population, the age adjusted incidence rate among blacks of
both sexes in 2005 was 1.0 per 100,000 per year, a decline of approximately 40% since
1976 when it was 1.7 per 100,000 per year. (19) Notably, the rise in incidence of CMM is
mostly accounted for by thin lesions (<1 mm) while the incidence of thick lesions (>1
mm) has remained static. (20)
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Figure 1. Age Adjusted Incidence and Mortality of Cutaneous Malignant Melanoma among
US Whites of Both Sexes
Data and figures are adapted from the US Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review
2005 (National Cancer Institute)

While the incidence of CMM has been steeply rising over the past half century, the rise in
the mortality rate has been much more modest. In 1975 the age-adjusted death rate for
CMM for both sexes in the US was 2.1 per 100,000 per year. In 2005, it had risen to 2.7
per 100,000 per year, an increase of only 29%. (19) [Figure 1] Considering selected birth
and gender cohorts separately, the death rate has been observed to rise and fall by
relatively small amounts from year to year. The difference between the rise in incidence
and the mortality rate, approximately an order of magnitude, has until now not been
adequately explained.

While over four-fifths of patients initially diagnosed with malignant melanoma present
with localized disease at the time of presentation, survival outcomes for all patients with
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melanoma have significantly improved over the past few decades. The projected 5 year
relative survival rate at the time of diagnosis for US patients with melanoma of any stage
during the period between 1995 and 2001 was 92%, a statistically significant increase
from the period 1974-1976 when 5 year survival was 80%. (21) For those melanoma
patients with evidence of regional spread beyond the primary site, the 5 year relative
survival drops to 64%. For those patients presenting with metastatic disease, the 5 year
survival is only 16%. CMM accounted for roughly three fourths of all deaths from skin
cancer in the United States (US) and accounted for 4.4% of all cancers in the US in 2006.
(21)

The physical and psychosocial consequences of a positive diagnosis of CMM are quite
serious. Some of the psychosocial ramifications commonly associated with a diagnosis of
CMM include anxiety and depression (22, 23) as well as considerable difficulty obtaining
life and health insurance or securing a home mortgage or pension plan (24). Depending
on the stage of the malignancy, the protocol for re-excision of a lesion varies among
clinicians. At many institutions, the margins mandated for re-excision of early stage
melanoma are the same as for dysplastic nevi with severe atypia, though that is not
universally the case. (25, 26) Though no longer recommended for patients with thin
lesions (27), in the case of more advanced disease there is a low but significant risk of
complications from sentinel node dissection that includes scarring, pain, sequelae
resulting from disrupted lymphatics, and complications due to anesthesia. (28) Since
patients who have been diagnosed with malignant melanoma have an increased risk of
developing an additional primary melanoma, there is broad consensus that melanoma
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survivors should undergo more frequent skin surveillance schedules with annual or semiannual visits to the dermatologist. Melanoma survivors undergo increased rates of
laboratory testing and diagnostic imaging that result in increased healthcare utilization
over their lifetime. (29) In some cases, first degree relatives of melanoma survivors may
be urged to undergo initial melanoma screening. (26)
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EPIDEMIOLOGY AND ETIOLOGY OF MELANOMA
Increases in the incidence of cutaneous malignant melanoma have been attributed to a
variety of both intrinsic and environmental factors such as genetics, ultraviolet radiation
exposure, latitude, and age. The extent to which each of these forces has contributed to
the rise in the incidence of CMM has been the subject of controversy; the relative
contribution of each factor toward the development of clinically relevant disease remains
uncertain.

Genetics
The most significant host factor to confer susceptibility to CMM appears to be a family
history of melanoma. (30) On a very basic level, it appears that an individual’s genetic
susceptibility to develop melanoma reflects the innate ability of the individual and their
blood relatives to withstand or adapt to ultraviolet light exposure as manifested by their
inherited skin phototype; both constitutive pigmentation as well as tanning, the adaptive
darkening of skin through up-regulation of melanocytes in response to UV radiation,
determines to a large extent an individual’s potential for protection from the mutagenic
events that lead to skin cancer. (31, 32)

It has been demonstrated that familial ethnic variations in skin type are directly related to
the presence or absence of polymorphisms in the melanocortin 1 receptor gene (MC1R)
which governs the activity of melanocyte stimulating hormone at its receptor in the skin.
(33-35) Fair skinned and/or red-headed individuals have a reduced ability to generate a
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tanning response to UV light because they tend to harbor a variant of the MC1R gene and
they subsequently suffer the highest incidence of melanoma. (36)

Being primarily a disease of light skinned individuals, CMM affects populations of
European origin an order of magnitude greater than dark skinned individuals. (6, 37)
During the period 1992-2002, the mean annual age-adjusted incidence of melanoma for
American whites per 100,000 was 18.4 while the incidence for African Americans was
calculated to be 0.8. (38) Other non-white ethnic groups in the U.S. demonstrated
similarly low incidence rates of melanoma per 100,000: Hispanics 2.3, Native Americans
1.6 and Asian Americans 1.0. (38)

Latitude
Among Caucasian populations, the incidence of CMM generally trends higher with
decreasing latitude, although this effect is complicated by varying patterns of recreational
travel among inhabitants of northern countries. According to 2001 data, the highest ageadjusted incidences of melanoma worldwide were found in Australia (men=
40.5/100,000, women= 31.8/100,000) and New Zealand (men= 36.7/100,000, women=
34.9/100,000). (6) In 2001, North America had the third highest incidence of melanoma
(men= 24.3/100,000, women= 16.2/100,000) followed in decreasing order by
Scandinavia, the rest of Northern Europe, Israel and Eastern Europe. (6, 19, 39)

Within North America, incidence does not clearly correlate with latitude. The 2004 age
adjusted incidence of melanoma per 100,000 in white populations of northern states such
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as New Hampshire (men= 30.8, women= 26.3), Vermont (men= 31.7, women= 29.0) and
Minnesota (men= 21.5, women= 15.8) are on par or higher than some southern tier states
such as North Carolina (men= 26.4, women= 23.2) and Texas (men=20.2, women=10.7).
(40) The white population of Hawaii has by far the highest melanoma rates (men= 89.3,
women= 56.8).

Ultraviolet Radiation Exposure
Among the environmental factors that may influence the incidence of melanoma, there is
broad but incomplete consensus as well as much debate over the idea that different rates
and patterns of exposure to solar and solar-type UV radiation drives the major differences
in melanoma incidence between historical, geographic, and age cohorts. (41-43)

The incidence of CMM does not appear to be proportional to total sun exposure as are
other non-melanoma skin cancers. Instead, intermittent sun exposure appears to confer a
greater risk of melanoma, suggesting that chronic sun exposure might be protective due
to host tanning responses. The relationship between intermittent sun exposure and an
increased incidence of melanoma are suggested by studies showing increased melanoma
incidence associated with total number of holidays abroad (44), accessibility to air travel
(45), and non-occupational sun exposure vs. occupational exposure (46).

Age
The risk of CMM increases significantly with advanced age. The probability of
developing an invasive melanoma for the cohort encompassing subjects from birth to 39
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years of age in the United States was 1 in 800 for men and 1 in 470 for women whereas
for the cohort 70 years of age and older, the probability for men was 1 in 80 and for
women was 1 in 178. (40)

Despite the correlation of incidence and increasing age, melanoma tends to affect the
young more than other solid tumor cancers. The mean age of melanoma diagnosis is 58,
roughly a decade earlier than other common cancers like those affecting the lung (70
years), colon (73 years), uterus (68 years), and prostate (68 years). (19) For patients aged
birth to 39, there is a significantly increased chance of developing melanoma (men=
0.13%, women= 0.21%) than of developing other cancers like lung cancer (men and
women= 0.03%) and colon cancer (men= 0.7%, women= 0.6%). Malignancies with
comparable rates to melanoma in the age 0 to 39 cohort include non-Hodgkin’s
lymphoma (men= 0.14%, women= 0.09%) and breast cancer in women (0.48%). (21)

Birth/Period/Cohort Analyses
Since researchers first began to study the rise in melanoma incidence, epidemiological
analysis has been brought to bear on the question of whether the increase in the incidence
of melanoma is real, artifactual or a combination thereof. A birth-cohort model would
postulate that the incidence of a disease varies when one identifies cohorts by the year
they were born whereas a period model would detect changes in incidence occurring over
specific periods of time.
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In the late 1980s, when mortality rates in the U.S. were rising more uniformly across all
age cohorts than they are presently, the rise in melanoma incidence was explained in
several studies by applying a birth cohort model to the epidemiologic data. (3, 47)

When a team of Yale researchers in the late 1980s compared birth cohort vs. period
cohort effects in data from the Connecticut tumor registry, the rise in melanoma
incidence was reported to be almost entirely explained by the birth cohort effect,
increasing in proportion to more recent birth cohorts. (47) Adding period as a variable
was reported not to have changed the outcome as would be expected with an artifactual
variable. Subsequently, the results of this study have been used as evidence that the
apparent rise in the incidence of melanoma has been primarily due to real increases in the
rate of disease.

In contrast, fitting data to a period-cohort analysis would allow for the possibility that
artifactual factors are contributing to the apparent increase in disease. Artifacts are
commonly introduced into epidemiologic analyses by phenomena such as increases in
disease detection due to the introduction of new tests or imaging technology as well as
changes in diagnostic criteria or an increase in the reporting of cases.

It should be noted that in the many decades since most of the birth cohort analyses were
conducted, the mortality rate of melanoma has slowed or reversed among various age and
birth cohorts. (19) It is not clear whether these analyses remain valid given the ever more
uniformly static death rate. Furthermore, artifactual changes occurring gradually over a
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long period of time may not be detectable with period analysis. Ultimately, the birth
cohort explanation for the rise in the incidence of melanoma is not a settled issue. (48)
Efforts to determine the relative contribution of a multitude of potential factors toward
the increase in melanoma incidence remains a challenging task.
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ARTIFACTUAL FACTORS
While the notion has been advanced that artifactual factors could account for no more
than a small portion of the rise in incidence of melanoma, (49) careful scrutiny of the
issue brings to light certain facts that appear to undermine this position. A summary of
these facts are briefly enumerated below and will be explored more deeply further in this
section.

First, the mortality rate of malignant melanoma has remained essentially static over
decades of steep rises in incidence. (19) Compared to most other aggressively fatal
cancers, the apparent dissociation between the incidence and mortality rate of CMM is
unusual and has until now not been well explained.

Secondly, biopsy rates have been rising and closely parallel the overall increase in
incidence. (15) Whereas the incidence of thin melanomas has been rising and almost
completely accounts for the overall rise in disease incidence, (20, 50) the incidence of
thick lesions has essentially remained static. (20) This preponderance of thin lesions with
no attendant decrease in thick lesions calls into question the success of surveillance and
prevention efforts and suggests that clinicians may be removing biologically indolent
lesions at an increasing rate.

Third, many studies have suggested that dermatopathologists cannot consistently agree
on the diagnosis of borderline melanocytic lesions. (49, 51-56) This raises the possibility
that factors other than diagnostic criteria, such as subjective bias, may be influencing the
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diagnosis of melanoma. Moreover, there is a significant risk of medico-legal liability in
the diagnosis of melanoma; this invites questions about the extent to which the threat of
litigation impacts diagnostic trends.

Death Rate, Disease Surveillance and Tumor Thickness
The 2005 age-adjusted death rate in the U.S. was 4.0 per 100,000 per year for males and
1.8 per 100,000 for females. (19) While the age adjusted death rate for both genders has
increased significantly since the mid 1970s, changes have occurred within a very narrow
range and trends in mortality according to the latest SEER data indicate that overall
mortality from melanoma was decreased during the period 1989-2001 as compared to the
period 1975-1981. The U.S. age-adjusted death rate rose from 2.1 in 1975 to a high of 2.8
in 1990 but has remained between 2.6 and 2.8 in all subsequent years. (19)

Some have argued that the stable death rate may be accounted for by better disease
prevention secondary to surveillance and early screening efforts. (11) However, others
have argued that this relationship is implausible (14). In order for screening and
prevention efforts to have mitigated mortality to a static rate, changes in surveillance and
screening must have exactly matched the rise in melanoma incidence over a long period
of time.

There is evidence to suggest that increased surveillance for skin cancer has led to an
increase in the reported incidence of melanoma (18, 57); however, the impact of
surveillance and prevention on the mortality of CMM is uncertain. The frequency of skin
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exams among the US population has not been well documented. According to an annual,
cross-sectional in-person household survey conducted by the National Center for Health
Statistics, the prevalence of lifetime skin cancer screenings was low with a mere 15% of
US workers reporting ever having had a skin exam in their lifetime. (58) While 69% of
respondents (26,225/38,124) reported seeing a primary physician over the past year, only
8% reported having had a skin exam in the past 12 months. In light of the fact that most
people do not perform self skin examinations and most people never see a dermatologist,
(58) it seems unlikely that surveillance and screening can account for the relatively stable
death rate.

Early and frequent screening would certainly explain the increase in the number of thin
lesions. However, it does not explain the stability in the rate of thick lesions. If advanced
melanomas were being prevented by screening measures, the incidence of thick lesions
should decrease over time. That is, again, unless the overall rise in incidence of disease
exactly matched the number of melanomas prevented -- an implausible scenario. It
appears that the increase in the number of thin melanomas being detected has had no
mitigating effect on the incidence of advanced disease. (20)

Likewise, if it is assumed that the incidence of melanoma has truly increased across the
whole population, then an increase in the number of people with advanced, fatal disease
should be observed. It should follow that since the majority of patients with advanced
disease never see a physician, the death rate should still rise significantly despite any
screening efforts. Nevertheless, this phenomenon has not been observed.
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Biopsy Rate
A recent study by Welch et al. that focused on patients 65 years of age and older reported
that increases in the average biopsy rate have roughly paralleled the increase in
melanoma diagnoses, rising 2.5 fold, from 2847 per 100,000 in 1986 to 7222 per 100,000
in 2001. (15) The rise in incidence in this cohort over the same time period was 2.4 fold,
from 45 to 108 per 100,000 population. The authors suggested that the proportionality of
the rise in biopsy rate to the rise in incidence in the setting of a static mortality rate
implied that the rise in incidence was due to “overdiagnosis—the increased incidence
being largely the result of increased diagnostic scrutiny and not an increase in the
incidence of disease.” (15)

Although higher socioeconomic status has been associated with a higher incidence of
CMM, the average thickness of lesions in an affluent cohort was found to be less than for
lower socioeconomic groups. (59) Subsequently, higher socioeconomic groups were
found to enjoy an overall better prognosis than lower socioeconomic groups – a finding
that raises the possibility that higher levels of wealth, corresponding to better healthcare
access and more frequent skin surveillance, may also result in the increased biopsy rate of
otherwise biologically benign lesions. (12)

Histopathologic Diagnosis
In contrast to CMM, dysplastic nevi are thought to be relatively clinically stable benign
lesions that possess some of the histopathologic features that characterize “frank”
malignant melanoma such as cytologic atypia, disordered proliferation, hyperchromasia
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and irregular nuclear contours. Most dermatologists consider dysplastic nevi one step
along a continuum of melanocytic lesions with increasingly malignant potential. (60) It is
commonly believed that certain dysplastic nevi represent precursor lesions to malignant
melanoma. (61-64)

Dysplastic nevi are often characterized as possessing “mild”, “moderate” or “severe”
cellular atypia. (65) The diagnostic criteria used by dermatopathologists to classify
melanocytic lesions are, however, less definitive for those borderline lesions that share
features of both benign and malignant disease. Histologic diagnosis is based on
evaluation of a collection of findings with no single element being diagnostic. There is no
gold standard for the diagnosis of malignant melanoma and there appears to be a
significant measure of subjectivity inherent in the process of pathologic diagnosis.

The reliability and reproducibility of histologic criteria used to denote dysplastic nevi has
not been well established. Historically, there has been a marked lack of consensus among
dermatopathologists in characterizing “borderline” dysplastic nevi. (66) With few
exceptions, most of the studies that have examined the reliability of the histologic
diagnosis of melanocytic dysplasia by examining diagnostic concordance between
different dermatopathologists have found inconsistent application of diagnostic criteria to
characterize the histopathology of melanocytic lesions. (49, 51-56)

One of the first studies to demonstrate a lack of consensus among dermatopathologists
evaluating borderline lesions was conducted by a German researcher in the mid 1980s.
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Fifteen dermatopathologists from around the world with a special interest in melanocytic
lesions were asked to evaluate a set of nine “precursors of malignant melanoma”. Single
slides were provided to participants without accompanying clinical information. Results
revealed that there was no agreement between the dermatopathologists in designating the
lesions “benign”, “pre-malignant” or “malignant” and there was little agreement in
diagnostic nomenclature. The author concluded that the ability of pathologists to render
reliable interpretations of biopsies containing atypical melanocytes was “limited”. (55)

Van der Esch and colleagues undertook an extensive international study in 1991 to
determine if pathologists’ diagnostic threshold for malignancy had changed over time.
(49) This landmark study has been widely cited since its publication as the strongest
evidence thus far that changes in diagnostic criteria used to evaluate melanocytic lesions
have not changed as a function of time. In this study, ten pathologists from various
international institutions read a total of 2506 slides of melanocytic lesions originally
biopsied in the 1930s, the 1950s and the 1980s. The diagnostic material originated from a
variety of international medical centers. In choosing slides for inclusion in the study, the
authors chose “to give greater emphasis to those lesions – the junctional and compound
naevi – where a change of opinion…as to malignancy would be most likely to arise”.
Original diagnoses of the slides were obtained and classified according to the original
diagnosis as “benign”, “dubious benign”, “dubious malignant”, or “malignant”.

The authors reported an astounding degree of agreement among participating pathologists
in classifying the study lesions; only 2.8% of lesions changed diagnostic categories upon
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re-diagnosis. However, despite the authors’ stated interest in focusing on “borderline”
lesions, it is important to note that only 108/2506 (4.3%) of the slides evaluated in the
study had an original diagnosis classified as “dubious benign” or “dubious malignant”.
With the majority of slides (N=1700/2506, 67%) originally diagnosed as “benign”, it is
not surprising that the authors found a modest “overall percentage of change” in
diagnostic category of 2.8%.

In contrast, although “dubious” diagnoses constituted only a small fraction of the total
pool of study lesions, nevertheless a large portion of the lesions originally classified as
“dubious benign”/ “dubious malignant” – over 1/3 -- were re-evaluated as frankly
“malignant”. Taking the “dubious malignant” slides alone from all periods, well over half
(23/41, 56%) were re-classified as frankly “malignant” while only 10/41 (24%) were reclassified as “benign” or “dubious benign”. Conversely, of the 692 lesions originally
diagnosed as “malignant”, participating pathologists re-confirmed the diagnosis in 665
(96%) of cases. (49) Taken in this light, the study by Van der Esch et al. appears to be
less than conclusive about the effect of time trends in the diagnosis of borderline
melanocytic lesions.

A similar study to that of Van der Esch, et al. was conducted around the same time by
Philipp, et al. in the United Kingdom. (54) Seventy lesions from each of three time
periods: the 1940s, 1950s and 1980s were chosen that included roughly 1/4 malignant
lesions, roughly 2/3 “junctional or compound naevi for which a change of opinion over
time was thought most likely to arise”, and about 5% “intradermal lesions which were
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considered less likely to be confused with malignant melanoma.” The published study
reported the results of re-diagnosis of the diagnostic material by only a single pathologist.
The authors reported that 206/210 slides (98%) were not reclassified with a different
diagnostic category than the originally issued diagnosis.

A study conducted at Yale in 1992 by Duray et al. compared the responses of five
observers reading 50 slides of “nevomelanocytic tumors” in a blinded fashion. (53) The
study demonstrated only “moderate” inter-observer agreement with regard to the
characterization of the histologic components of dysplastic nevi.

In a 1993 study, Duncan et al. found a high concordance rate (77%) among five
dermatopathologists asked to grade a set of previously diagnosed melanocytic lesions in
distinguishing between benign nevi, various grades of dysplastic nevi and melanoma.
(67)

A study undertaken by a Danish team of dermatopathologists, Hastrup et al., examined
the inter-observer reproducibility of the various histological criteria used to distinguish
nevi as “dysplastic”. (52) After analyzing the responses of four observers asked to rediagnose a set of previously diagnosed melanocytic lesions, they found “slight” to “fair”
inter-observer reproducibility of histological features, particularly cytological features.

In 1995, Farmer et al. found “moderate” concordance (kappa=0.50) between eight
“expert pathologists” rating a set of biopsies of 37 melanocytic lesions as “benign”,
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“malignant” or “indeterminate”. (68) Thirty five percent of the cases had complete
agreement, 27% had one discordant observer and 38% had two or more discordant
observers.

Corona and colleagues measured agreement among four dermatopathologists evaluating a
large set of mixed melanomas and benign pigmented lesions. (69) They reported an
overall kappa value of 0.61 for melanoma vs. benign lesion but a poorer level of
agreement for presence of absence of specific histologic features.

A 1997 study by Weinstock et al. compared agreement among five dermatopathologists
and two “melanoma experts” grading a heterogeneous collection of 112 biopsy slides of
melanocytic tumors with the help of a photomicrographic atlas. (51) Graders’
observations were assigned points according to a 5-point scale that grouped responses
into different categories according to pre-determined diagnostic terms, i.e. “no
melanocytic dysplasia”, “melanocytic dysplasia with slight, moderate or severe cellular
atypia” or “melanoma”. When raters’ responses were grouped in a dichotomous fashion
(benign or malignant) and compared against each other, the intra-class coefficient was
0.58, suggesting a significant level of discordance.

Considering the available literature on the subject as a whole, a substantial majority of
the prior studies examining concordance rates of dermatopathologists reading
melanocytic lesions have not reported robust levels of agreement, particularly in the case
of borderline lesions. Of the nine studies mentioned above, none except Duncan et al. and
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Phillipp et al., demonstrated high levels of agreement in the case of borderline lesions.
The evidence so far seems to suggest that dermatopathologists, whether or not they agree
on normative diagnostic criteria, have not historically achieved consistently high levels of
concordance in the diagnosis of borderline melanocytic lesions.

Medicolegal Liability
There have been few studies to date examining the influence of malpractice claims and
legal liability on the decision making behavior of pathologists. In an examination of the
records at a professional liability insurer in California, researchers found that 8.6% of all
malpractice claims generated against pathologists involved the words “skin cancer”
and/or melanoma. (70)

In an analysis of published verdicts and jury settlements on a popular legal database, 26
out of the 171 cases examined involved the underdiagnosis of melanoma on skin biopsies
by dermatopathologists. (71) The results of this study corroborated the work of Troxel et
al. in revealing that “false-negative” diagnoses of melanoma constitute the most common
claim against surgical pathologists.
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HYPOTHESIS
It is hypothesized that the diagnostic threshold of malignancy for the histopathologic
diagnosis of melanoma has decreased over the past 20 years; that dermatopathologists are
diagnosing more melanoma now than in the period 1988-1990, in lesions that would
previously have been regarded as dysplastic nevi. This study has sought to determine if
diagnostic decision-making in a cohort of dermatopathologists evaluating severely
atypical melanocytic lesions and thin superficial spreading melanomas has changed as a
function of time over the two decades that elapsed between the late 1980s and 2008.

STATEMENT OF PURPOSE
The dramatic increase in the incidence of malignant melanoma over the past few decades
has been attributed to an array of possible factors, both artifactual and real. One underexplored factor that could help to explain the apparent paradox posed by the dissonance
of incidence and mortality rates, is the possibility that dermatopathologists’ threshold for
rendering a diagnosis of melanoma may have changed over time. Given the dramatic
increase in biopsy rates over the past 20 years, it is plausible that shifts in diagnostic
decision-making by dermatopathologists could have occurred over the same period. Such
shifts, potentially due to increased vigilance in the face of heightened legal liability, may
have resulted in an increase in the diagnosis of melanoma in lesions that would have been
otherwise diagnosed as benign in the past- a fact that may explain some of the
discrepancy between incidence and mortality. In light of the significant morbidity and
cost associated with a diagnosis of CMM, it is important that any potential source of
overdiagnosis be identified and mitigated.

22
METHODS
A search was conducted within the surgical pathology computer database of the
Massachusetts General Hospital (MGH) for the years 1988 to 1990. The entire database
was searched with the terms “dysplastic nevus”, “severe atypia” and “superficial
spreading malignant melanoma”. All pathology reports that contained any of the
aforementioned terms were collected and were subsequently reviewed in order to
determine suitability for inclusion in the study. Slides of dysplastic nevi were deemed to
meet inclusion criteria if the diagnosis mentioned “severe atypia” or “moderate to focally
severe atypia”. Particular preference was given to slides of dysplastic nevi with severe or
moderate to focally severe atypia of the “intraepidermal component”. Slides of malignant
melanoma were considered suitable for inclusion if they contained the term “superficial
spreading melanoma” and if they contained a designation of Clark level II, III or II/III.
Slides of biopsies originally processed at outside institutions were excluded. Slides that
contained the terms “spindle cell”, “blue nevus”, or “Spitz nevus” were also excluded.

A total of 1207 pathology reports were generated by the computer search. According to
the pre-stated criteria, the total number of suitable cases of dysplastic nevi obtained was
28. Seventy nine suitable cases of superficial spreading melanoma were obtained.

In light of the possibility that the re-classification of any of the non-melanoma study
slides as invasive melanoma could have lead to a medico-legal dilemma, consideration
was given to the fact that a 15 year interval had elapsed between the study and the
original diagnosis. It was concluded that the study could proceed with reasonable
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assurance that study slides would not be re-diagnosed as advanced melanoma since the
biologic aggressiveness of this type of tumor would have in all likelihood declared itself
in a much shorter time interval and the consequences would already have been known
and addressed. Furthermore, the standard of care at the MGH at the time that these
biopsies were originally performed mandated conservative re-excision of 1 cm for
severely dysplastic nevi – the same level of care performed for patients diagnosed with
early stage superficial spreading melanoma.

Search: MGH surgical pathology files from years 1988-1990 for:
(“dysplastic nevus” AND “severe atypia”) OR “superficial spreading melanoma”

Yield: pathology reports for:
28 cases of LCDN with “severe”, or “moderate to focally severe” atypia
12 cases of SSMM with Clark level II, III or II/III (depth range 0.24mm to 0.74mm)

Obtained: Original diagnostic material (full biopsy blocks) for all 40 cases.
Senior staff MGH dermatopathologist selected one representative slide from each case.

Review: Each of the 40 slides is to be re-evaluated as either “Melanoma” or
“NOT Melanoma” by:
- All dermatopathologists of record that had issued a diagnosis for at least one
of the 40 slides.
- All current MGH dermatopathology staff

Figure 2. Schematic Diagram of the Experiment
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Twenty eight cases of dysplastic nevi and twelve cases of superficial spreading
melanoma (depth range 0.24mm to 0.74mm) were chosen for inclusion in the study. The
entire set of slides corresponding to the 40 cases selected for the study were reviewed by
a senior staff dermatopathologist at MGH in order to select one representative slide from
each case as free of artifacts as possible. The dermatopathologist that selected
representative slides did not have access to the pathology reports corresponding to the
cases reviewed. The total number of study slides was fixed at 40 in order to make the reevaluation of the study slides a manageable enterprise and thus increase the chances that
participating dermatopathologists would re-evaluate the slides in a timely manner. All
slides were anonymized by concealing the accession numbers with white tape. All 40
slides were shuffled randomly, numbered 1 to 40, and placed in a slide folder. A
schematic of the study protocol has been provided below. [Figure 2]

The identities of the original dermatopathologists that had signed out the diagnoses for
each of the 40 study cases were noted and recorded. A total of 9 dermatopathologists on
staff at MGH during the years 1988-1990, singly or in tandem, issued the original
diagnoses of the 40 study slides.

The identities of the 9 original dermatopathologists were anonymized and designated by
letters of the alphabet. The number of slides read by each dermatopathologist ranged
from 1 to 12 with a mean of 7.2 slides per reader. Thirteen of the study slides (32.5%)
had originally been diagnosed jointly by 2 dermatopathologists. Three of the jointly
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diagnosed slides were co-diagnosed by a dermatopathologist (L) that was deceased at the
time the study was conducted. [Figure 3]

Figure 3. Number of Study Slides Diagnosed Singly or Jointly by each Dermatopathologist,
as Designated by a Letter of the Alphabet.

Dermatopathologists were recruited to participate in the study. Participants were selected
if they fulfilled either of two criteria:

1. They had rendered a diagnosis on one of the slides selected for the study or,
2. They were currently serving on the staff of the dermatopathology department at
MGH at the time the study was conducted.

Therefore, all participating dermatopathologists were currently serving or had formerly
served on the staff in the Department of Dermatopathology at the Massachusetts General
Hospital. Attempts were made to recruit all of the original diagnosing
dermatopathologists as well as all faculty members in the MGH Department of
Dermatopathology.
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Participating dermatopathologists were asked to re-evaluate all the slides and decide
whether the biopsy represented “melanoma” or “not melanoma”. To facilitate comparison
of diagnoses, all 40 original official diagnoses of the study slides were subjected to a
dichotomous categorization whereby they were designated either “malignant melanoma”
or “not malignant melanoma”. In this way, all slides of dysplastic nevi were considered
“not melanoma”. A chart has been provided that illustrates all potential responses by
study participants [Figure 4]. Slides with an original diagnosis of “not melanoma” were
coded “0” and slides with an original diagnosis of “melanoma” were coded with a “1”.

Participating dermatopathologists received a cover letter explaining the procedures for
grading study slides and recording diagnoses. In order to achieve a degree of participant
blinding to the primary aims of the study, and in order to approximate as much as
possible, a non-biased diagnostic setting, the cover letter contained a description of the
study limited to a simplified and general explanation of the study’s aims. All participants
were told that at the conclusion of the study they would be apprised of the specific aims
of the study, and given a copy of the protocol and the working manuscript.

After the cover letter had been sent to selected dermatopathologists and consent had been
obtained, the slide set was sent sequentially to responding dermatopathologists along with
instructions for reviewing the slide set and a grading sheet for recording diagnoses. The
grading sheet allowed participating dermatopathologists to check a box for each
numbered slide designating the slide “melanoma” or “not melanoma” as well as a space
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Total Melanoma

12

Figure 4. Study Response Tally Outline
The diagnoses of forty study slides were dichotomized as “melanoma” (white= 0) or “not melanoma (black= 1).
Potential study participants included nine dermatopathologists (A-F, J-L) that had rendered an original diagnosis
on at least one of the study slides as well as current MGH staff dermatopathologists (A, F-I).

Key

DP = Dermatopathologist
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in which they were instructed to add additional comments about the slides if they so
desired.
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RESULTS
Five dermatopathologists currently on staff at MGH at the time of the study evaluated the
slide set; two of the current staff members belonged to the original set of 9
dermatopathologists that had rendered an original diagnosis for one or more of the study
slides.

Of the original 9 dermatopathologists that diagnosed one or more of the study slides, 3
successfully completed re-evaluation of the slide set. One additional member of the
original set of 9 diagnosing dermatopathologists was in the process of re-evaluating the
slide set at the time of this writing. One of the original dermatopathologists had since
passed away. At the time of this writing, five of the original diagnosing
dermatopathologists had not responded to study recruitment attempts.

All study participants diagnosed significantly more melanomas than the 12 melanomas
that were originally included in the slide set. [Figure 5] The mean number of melanoma
diagnoses for all 6 graders was 19.7 (median= 19.5, range 16-23), an increase of 64%.

There were 6 instances where a dermatopathologist disagreed with his or her own
diagnosis 20 years ago. These changes of within-rater diagnosis went from benign to
malignant in 5 of the 6 new diagnoses. [Figure 5]

The Cohen kappa statistic was used to determine the degree of agreement between
diagnoses. The free-marginal kappa as a measure of inter-rater agreement was
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Mean revised
melanoma yield: 19.7
Figure 5. New Diagnoses of Study Slide Set by Participating Dermatopathologists (DPs)
compared to the original diagnoses.
There were 40 slides in the study slide set: 28 dysplastic nevi and 12 superficial spreading melanomas. Six DPs reviewed
the study slides. Diagnoses were given a dichotomous categorization: 0 = “not melanoma and 1 = “melanoma”. Individual
DPs are designated by letters of the alphabet. Three of the six participating DPs (A,B, and F) had rendered an original
diagnosis on at least one of the study slides and are represented by a yellow background. DPs who did not render one of the
original diagnoses (G, H, and I) have a white background. There were a striking number of instances (21%) where the
original diagnosis of “not melanoma” was overturned.

Key
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ascertained by comparing the diagnoses of all 6 dermatopathologists that re-evaluated the
slides. The free-marginal kappa was also used as a measure of temporal concordance –
the relative difference between raters’ diagnoses in 2008 against the diagnoses originally
rendered for the study slides in 1988-1990. Temporal concordance was calculated
retrospectively between each participating dermatopathologist and the original
diagnosing dermatopathologists, whether they were one in the same or not.

The Cohen kappa coefficient is a value that may be generated by comparing sets of
paired observations. (72-74) The kappa statistic describes two observers’ level of
agreement as compared to chance. The kappa statistic ranges between 0 and 1 with
increasing value proportional to level of agreement. The “free-marginal” kappa statistic
is used in place of the “fixed-marginal” kappa statistic when raters are not obliged to rate
a particular number of items in one way or another.

There is considerable disagreement among statisticians about what value of kappa
constitutes a sufficient level of agreement. Landis and Koch devised a widely accepted
interpretive scale that identified kappa values of 0.61-0.8 as indicating “substantial
agreement”. (74) [Figure 6] This scale was later corroborated by Rietveld and Van Hout.
(75) More recently, Shrout proposed a revision of Landis and Koch’s original scale,
suggesting that kappa levels of 0.81 to 1.0 should indicate “substantial agreement”. (76)
A more conservative interpretation of kappa was proposed by Kripendorff, who declared
that “definite conclusions” about the kappa statistic can only be drawn for values of 0.8
or greater. (77) Values below 0.67, according to Krippendorff, should be “discounted”. In
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contrast, some prominent psychiatric researchers have cited kappa values of 0.5 or 0.6 as
“adequate” (78).

Figure 6. Interpretation of the Cohen Kappa Coefficient
The Cohen Kappa coefficient ranges from -1.0 to 1.0. There is considerable controversy over how to interpret
Kappa values. One common method of interpretation relies on an arbitrary scale as defined by Landis and Koch.
Another common approach proceeds from the statistical definition of the Kappa coefficient with -1.0 representing
perfect disagreement below chance, 0.0 representing agreement equal to chance and 1.0 representing perfect
agreement above chance.

For the purposes of this study, only kappa values generated from the data that fall well
below or above the “grey area” of 0.61-0.8 are discussed in a qualitative manner. Despite
the lack of a clear threshold for an acceptable level of agreement, the magnitude of the
mean kappa statistic for the group as a whole, representing temporal discordance between
the diagnosing dermatopathologist in 1988-1990 and those dermatopathologists rereading the slides in 2008, still reveals in an imperfect way, to what degree diagnostic
behavior employed by this group of dermatopathologists differs from those reading the
slides 20 years prior.

The mean free-marginal kappa values describing temporal concordance between each of
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the 6 participating dermatopathologists and the original diagnosing dermatopathologists
for all study slides was 0.53 (range 0.15- 0.7) [Figure 7]. When comparing temporal
concordance for lesions originally diagnosed “Melanoma”, the mean marginal free kappa
was 0.86 (range 0.5- 1.0). [Figure 8] For lesions originally diagnosed “not melanoma”,
the mean marginal free kappa was 0.39 (range 0.0- 0.64). [Figure 9]
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Figure 7. Free-marginal Kappa Values Representing Temporal Concordance between Each
Participating Dermatopathologist and Original Diagnosing Dermatopathologists for All Study
Slides.
Kappa values representing concordance of participating dermatopathologists with the original diagnosis for all study
slides did not surpass 0.7 for all but one dermatopathologist. The overall mean agreement between the 6 participating
dermatopathologists and the diagnosing dermatopathologist for all study slides was represented by a mean kappa
value of 0.53.
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Figure 8. Free Marginal Kappa Values Representing Temporal Concordance between Each
Participating Dermatopathologist and Original Diagnosing Dermatopathologists for Slides
Originally diagnosed “Melanoma”.
In evaluating slides originally diagnosed as “Melanoma”, participating dermatopathologists demonstrated a high
level of concordance with the original diagnosis. Half the participating dermatopathologists had perfect agreement
with the original diagnosis of melanoma.
Overall mean agreement between the 6 participating dermatopathologists and the diagnosing dermatopathologist for
lesions diagnosed “melanoma” was represented by a mean kappa value of 0.86.
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Figure 9. Free Marginal Kappa Values Representing Temporal Concordance between Each
Participating Dermatopathologist and Original Diagnosing Dermatopathologists for Slides
Originally Diagnosed “NOT Melanoma”.
In evaluating slides originally diagnosed “NOT Melanoma”, participating dermatopathologists demonstrated a low
level of concordance with the original diagnosis. Overall mean agreement between the 6 participating
dermatopathologists and the original diagnosing dermatopathologist for lesions diagnosed “not melanoma” was
represented by a mean kappa value of 0.39.

In considering inter-rater agreement between all 6 participating dermatopathologists,
there was a large difference in degree of agreement depending on the original diagnosis.
For all study slides, participating dermatopathologists had a low inter-rater agreement
rate represented by a mean free-marginal kappa value of 0.38. Only considering lesions
originally diagnosed “not melanoma”, participating dermatopathologists had a very low
agreement rate represented by a mean free-marginal kappa of 0.22. For lesions originally
diagnosed “melanoma”, the rate of inter-rater agreement was represented by a relatively
high mean free-marginal kappa value of .74.

Considering temporal concordance in terms of what proportion of raters agreed with the
original diagnosis, unanimous agreement with the original diagnosis was achieved in
66.7% of slides originally diagnosed “Melanoma”. In 25% of slides originally diagnosed
“Melanoma” 5/6 raters agreed with the original diagnosis. In 8% of slides, 4/6 raters
agreed with the original diagnosis. [Figure 10]
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Figure 10. Concordance with original diagnosis among participating DPs: Melanoma Slides Only
Of the 12 slides originally diagnosed “Melanoma” participating DPs had varying levels of concordance with the original
diagnosis. There was unanimous agreement (6/6) among participating DPs with the original diagnosis in approximately
2/3 of slides originally diagnosed as “Melanoma.

For slides originally diagnosed “Not Melanoma”, unanimous agreement with the original
diagnosis was achieved in only 17.9% of slides originally diagnosed “Not Melanoma”. In
32.1% of slides originally diagnosed “Not Melanoma” 5/6 raters agreed with the original
diagnosis. 14.3% of cases had 4/6 raters agree with the original diagnosis. In 21.4% of
slides originally diagnosed “Not Melanoma”, there was no agreement one way or the
other among the 6 raters. In 14.3% of cases, a majority of raters (4/6) overturned the
original diagnosis of “Not Melanoma”. [Figure 11]

Although the original diagnoses of the study slides do not represent a “gold standard” for
diagnosis of malignant melanoma, it may be instructive to momentarily regard them as
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Figure 11. Concordance with original diagnosis among participating DPs: NOT Melanoma
Slides Only
Of the 28 slides originally diagnosed “NOT Melanoma” participating DPs had varying levels of concordance with
the original diagnosis. Only 1/6th of slides originally diagnosed as “NOT Melanoma” had unanimous (6 out of 6)
agreement among participating DPs with the original diagnosis. 1/3 of slides originally diagnosed “NOT
Melanoma” had one dissenting DP. 1/5 of slides originally diagnosed “NOT Melanoma” had no agreement
whatsoever. In 14.3% of slides originally diagnosed “NOT melanoma” a majority of DPs (4/6) overturned the
original diagnosis.

such in order to examine participants’ responses as if their diagnoses were a “test” for
detecting malignant melanoma. Taking the original diagnoses from 1988-1990 as the
“true” diagnoses, participants’ responses had a mean positive predictive value for
detection of malignant melanoma of 0.58 (range 0.39- 0.69), a mean sensitivity of 0.93
(range 0.75- 1.0) and a mean specificity of 0.7 (range 0.5- 0.82).
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DISCUSSION
The chief aim of this research was to determine whether diagnostic behavior by
dermatopathologists in the evaluation of borderline melanocytic lesions has significantly
changed over a 20 year period. The results of this experiment suggest that it has. This
study has demonstrated three principal findings concerning a select group of
dermatopathologists practicing at a major medical center: One, there is ample
disagreement about the malignancy status of lesions originally diagnosed as benign in
1988-1990. Two, diagnosis of borderline lesions trended toward “malignant” for all study
participants; in re-evaluation of a slide set that contained 12 original diagnoses of
“malignant melanoma”, the mean number of revised melanoma diagnoses by the 6 study
participants was 19.7, an increase in 64% from the original number of melanoma
diagnoses. Three, there are adequate levels of agreement about the malignancy status of
lesions originally diagnosed as “malignant” in 1988-1990.

If dermatopathologists have changed their diagnostic habits, they may not have done so
in a way that affects all diagnostic categories. It is reasonable to wonder whether changes
in diagnostic habits, if they have truly occurred, have affected the diagnosis of
“borderline” lesions while leaving melanocytic lesions with a lesser degree of atypia
relatively unaffected. Moreover, unlike the transient rise in incidence of prostate cancer
in the 1980s which was attributable to the rapid implementation of prostate specific
antigen testing, artifactual changes in melanoma incidence such as would be seen in the
case of changing subjective diagnostic habits would likely be more gradual and might not
be observed in time-cohort model analysis.
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Many authors have advanced the argument that some part of the rise in the incidence of
melanoma can be attributed to artifactual causes such as increase in biopsy rate (15),
changes in histopathologic criteria (8, 13, 14, 39), and the existence of a nonmetastasizing form of thin melanoma. (9, 16, 17, 20, 79) As with these theories, it
remains difficult to quantify the impact that changes in diagnostic behavior by
dermatopathologists may have had on the apparent incidence rates of melanoma.

This study corroborates previous research showing that dermatopathologists achieve little
to no consensus on the diagnosis of borderline melanocytic lesions. (49, 51-53, 55, 56,
68, 69) For the lesions whose diagnosis of “not melanoma” was overturned by the study
participants, there was poor agreement in most cases, suggesting that if
dermatopathologists have lowered their diagnostic threshold, they do not appear to have
done so in a uniform manner.

While it could be argued that the trend toward malignant diagnosis revealed by this study
reflects the fact that dermatopathologists have better learned to identify malignant
melanoma, epidemiologic evidence does not support this; although the number of lesions
being biopsied has increased over the past 20 years, there is little evidence that better
histopathologic detection has resulted in better outcomes.

With regard to borderline melanocytic lesions, diagnostic criteria appear to go only so far
toward enabling a dermatopathologist to render a final diagnosis. It seems plausible that
two dermatopathologists may ascribe similar histopathologic descriptors to a given lesion
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yet each render a different ultimate diagnosis; one may call the lesion “not malignant”
while the other may call it “malignant”, yet they both describe the lesion using similar
technical language. As this study demonstrates, individual dermatopathologists do not
necessarily agree with themselves, let alone with each other, when the malignant status of
a lesion is concerned. Specific histopathologic diagnostic criteria for diagnosing CMM
need not have changed for this to be the case. What has possibly changed is that the
decision-making involved in the subjective final determination of the ultimate diagnosis
of a melanocytic lesion, as motivated perhaps by fears of medico-legal liability (70), has
slowly pushed lower the “borderline” that is the threshold for diagnosing malignancy.

Limitations
A generalization of the results of this study is limited by a number of factors:

First, the number of slides originally diagnosed as “malignant melanoma” comprised only
30% of the total slide set. The likelihood of detecting a change in both directions is
therefore biased toward the set of dysplastic nevi trending to malignancy.

We purposefully selected “borderline” dysplastic nevi -- biopsies that represented the
severest grade of atypia. Pathology reports for the dysplastic nevi used in this study often
contained language that tempered the diagnosis with caveats and admonitions to perform
“conservative re-excision”. In some cases, the diagnosing pathologist, though rendering
an ultimate diagnosis of dysplastic nevus, added notes that expressed equivocation about
the diagnosis and sometimes wrote “melanoma cannot be ruled out”. In contrast, none of
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the pathology reports for the superficial spreading melanomas expressed any
equivocation about the diagnosis. In trying to select “borderline” melanomas, no
selection criterion other than “thinness” could be reasonably applied to the melanoma
cases. Despite the broad debate about the “borderline” nature of severely dysplastic nevi,
there is little discussion at large about “borderline” melanomas. This study was designed
according to the assumption that invasive but thin melanomas would be the best
examples of “borderline” lesions on the malignant side of the borderline.

Participants in this study received no clinical or demographic information about the
patients whose biopsies were selected for review. Without the aid of information
regarding the age of the patient, the body part involved and the clinical history of the
patient, one could argue that participants were at a significant disadvantage compared to
the original diagnosing dermatopathologist. It is true that pathologic diagnosis is often
informed by clinical context and demographic data. However, many of the original
pathology reports for the biopsies used in this study detailed personal or family history of
malignant melanoma which, if disclosed, certainly could have skewed results in the
opposite direction.

It could be argued that study participants might have taken a different attitude toward
diagnosis of slides for a research study than they would toward diagnosis of slides in the
course of their daily work. It is plausible that diagnoses rendered to direct a real patient’s
ultimate disposition might be generated with an eye toward legal and peer scrutiny – after
all, a human life is on the line and the potential consequences of “false negative” errors
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pose a formidable disincentive for less conservative behavior. Since the participants read
the study slides with no medico-legal or clinical consequences, they could potentially
afford to be less conservative than they might be in daily practice. In light of this, the true
extent of melanoma re-diagnoses could be larger than the results disclose.

While the limitation placed on participating dermatopathologists in this study to render a
dichotomous diagnosis made comparison between study participants relatively easy, it
made comparison with the original diagnosis problematic. The fact that the same
categories available for diagnosis at the time that the biopsy was originally read were not
available during re-evaluation of the slides during the study makes the comparison of
diagnoses one step removed from a direct comparison. The latitude normally allowed in
wording diagnoses and the fine gradations of language used to characterize melanocytic
lesions allow highly nuanced diagnoses that guide treatment more than the simple
categories of “benign” and “malignant”. However, as an ultimate designation of
“malignant” or “not malignant” is surely an important decision for any
dermatopathologist, it is reasonable to assume that two diagnoses by the same
dermatopathologist would not change much depending on how nuanced his/her answer
was allowed to be.

This study examined the responses of a relatively small number of dermatopathologists.
The results reported here are not necessarily representative of dermatopathologists in
general.
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Lastly, dermatopathologists normally have a larger sample of diagnostic material to
review when evaluating cases. Whereas cases in the real world are usually represented by
whole blocks of a dozen or more slides, this study limited each case to one representative
slide.

Conclusion
The results of this study support the hypothesis that dermatopathologists are more likely
to diagnose melanoma in biopsies of lesions that were diagnosed as borderline dysplastic
nevi 20 years ago. It is far from clear whether this phenomenon may be extended to
dermatopathologists in general and whether it could account for any of the apparent rise
in the incidence of melanoma.

These findings also underscore previous research demonstrating that dermatopathologists
are not consistently able to achieve consensus in diagnosis of borderline melanocytic
lesions.

An expanded version of this study would help to further characterize and refine these
conclusions. It would seem worthwhile to extend this study to dermatopathologists at
different academic medical centers as well as to dermatopathologists in private practice.

Furthermore, the effect of time as a factor on the change in diagnostic behavior of
dermatopathologists reading borderline lesions could perhaps be better understood if the
study were repeated with the same participants but this time reading a second set of study
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slides that were originally diagnosed within the past year. This would allow a more true
comparison of general histopathologic diagnostic habits at two separate points in time.
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